Updated Data from the Phase 1/2 Study of Olomorasib in KRAS

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in...

Related Keywords

United States , American , Joe Fletcher , David Hyman , Prnewswire Eli Lilly , Eli Lilly , Timothy Burns , Exchange Commission , American Society Of Clinical Oncology , Merck Sharp Dohme , Lilly United States , Linkedin , Facebook , Merck Co Inc , Cancer Research , Instagram , Clinical Oncology , Associate Professor , Pittsburgh Medical Center Hillman Cancer , Merck Sharp , Private Securities Litigation Reform Act , United States Securities ,